From: THE MEDICAL NEWS
The prognosis for nearly three-quarters of elderly patients on
intensive chemotherapy for acute myeloid leukemia (AML) is poor,
with a median survival of less than six months, according to a
study published online today in Blood, the journal of the American
Society of Hematology. AML is the most common form of acute
leukemia among adults and is a rapidly growing cancer of the bone
marrow that requires immediate treatment. The average age at
diagnosis is 67, and more than 12,000 people will be diagnosed with
AML this year (according to the National Cancer Institute).
Respond to this topic on your own blog
Click and press Ctrl+C to copy and paste this discussion on your blog or site
Related Articles
SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication
SuperGen, Inc., a pharmaceutical company dedicated to the discovery
and development of novel cancer therapies, announced that Eisai
Inc. today released information regarding a randomized Phase III
clinical trial of Dacogen® (decitabine) for Injection in
elderly patients with acute myeloid leukemia (AML). The comparator
in this trial was low-dose cytarabine, a chemotherapy agent, or
supportive care.
Brothers Of Prostate Cancer Patients Undergo More Diagnostic Activities
The brothers of men with prostate cancer are at an increased risk
of prostate cancer diagnosis because of increased diagnostic
activity and not necessarily because they carry a genetic mutation
that increases risk of the disease, according to a study published
online August 19 in The Journal of the National Cancer Institute...
Brothers Of Prostate Cancer Patients Undergo More Diagnostic Activities
The brothers of men with prostate cancer are at an increased risk
of prostate cancer diagnosis because of increased diagnostic
activity and not necessarily because they carry a genetic mutation
that increases risk of the disease, according to a study published
online August 19 in The Journal of the National Cancer Institute...
New therapies increase survival rates in post-transplant liver cancer patients
A recent study found that sirolimus-based immunosuppression
following liver transplantation in patients with non-resectable
hepatocellular carcinoma (liver cancer) significantly increases
survival rates for this patient population. Results of this study
appear in the April issue of Hepatology, a journal published by
Wiley-Blackwell on behalf of the American Association for the Study
of Liver Diseases (AASLD).
Study Notices Link Between Male Cancer Survivors And Sexual Dysfunction
It may be a good idea for male cancer survivors to take nutritional
supplements like zinc and vitamin C, as a new study suggests that
some of the side effects from testosterone deficiency caused by
chemotherapy treatments could lead to erectile dysfunction.
Research published in the journal Cancer reveals that testosterone
deficiency can be a late side effect of radiation therapy and
chemotherapy that affects approximately 15 percent of young male
cancer survivors.